References
- Ehrmann D A. Polycystic ovary syndrome. New Engl J Med 2005; 352: 1223–1236
- Practice Bulletin ACOG. Clinical management guidelines for obstetrician-gynecologist: number 41. Obstet Gynecol 2002; 100: 1389–1402
- Ehrmann D, Rychlik D. Pharmacologic Treatment of polycystic ovary syndrome. Semin Reprod Med 2003; 21: 277–283
- Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005; 11: 277–291
- Hillard P J. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am 2005; 34: 707–723
- Buggs C, Rosenfield R L. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34: 677–705
- Archer J S, Chang R J. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 737–754
- Guzick D S. Polycystic ovary syndrome. Obstet Gynecol 2004; 103: 181–193
- Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care 2002; 7(Suppl 3)19–26
- Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003; 8: 37–51
- Mansour D. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. Eur J Contracept Reprod Health Care 2002; 7(Suppl 3)35–41
- The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19–25
- Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004; 89: 2817–2823
- Palep-Singh M, Mook K, Barth J, et al. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care 2004; 30: 163–165
- Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89: 1592–1597
- Batukan C, Muderris I I. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006; 85: 436–440
- Golland I M, Elstein M E. Results of an open one-year study with Diane35 in women with polycystic ovary syndrome. Ann NY Acad Sci 1993; 687: 263–271
- Diamanti-Kandarakis E, Baillargeon J P, Iuorno M J, et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003; 88: 1927–1932
- Dahlgren E, Landin K, Krotkiewski M, et al. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1998; 13: 2706–2711
- Mastorakos G, Koliopoulos C, Deligeoroglou E, et al. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006; 85: 420–427